CNS pipeline · person

Ludwig Hantson, PhD

Director of Ionis Pharmaceuticals appointed effective June 4, 2026. A veteran biopharmaceutical executive with more than 30 years of leadership experience, he served as Chief Executive Officer and a board member of Alexion from 2017 to 2021, prior to its acquisition by AstraZeneca, and earlier held senior roles at Baxter, Novartis and Johnson & Johnson.

  • 1 company

Current roles

Appears with

People sharing a company with Ludwig.

People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.